Project Grant R44AI104034

This Project Grant award from the National Institutes of Health's National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,010,081 to Emory University to conduct research focused on identifying potential immune modulatory therapies for Alzheimer's disease that fall within a "Goldilocks zone" - where disease modification can be achieved with minimal or no damage. The key products and services to be delivered under this 5-year grant include: Systematically evaluating the...

The National Institute on Aging (NIA) awarded a $622,086 Project Grant (CFDA 93.866 Aging Research) to The Johns Hopkins University to elucidate the role of the NOD2/RIPK2 signaling pathway in microglial activation and neuroinflammation in Alzheimer's disease (AD). The project aims to characterize the mechanisms by which amyloid-beta oligomers interact with the NOD2 receptor, leading to RIPK2-mediated inflammatory responses that contribute to neurodegeneration in AD. Key objectives include:...

The U.S. National Institute on Aging (NIA) awarded a $506,451 Project Grant (CFDA 93.866 - Aging Research) to 3P Biotechnologies, Inc., a for-profit biotechnology company, to develop a targeted exosomal delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases such as Alzheimer's disease. The project aims to optimize the delivery of siRNA against the inflammatory regulator NF-kB using folic acid-functionalized exosomes derived from bovine colostrum....

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $787,103 to Vanderbilt University to support research on using small interfering RNA (siRNA) lipid conjugates to target brain myeloid cells, including microglia and macrophages, for the treatment of Alzheimer's disease. The 5-year project aims to comprehensively analyze siRNA-mediated gene and protein silencing activity in brain myeloid cells, evaluate performance in aging and...

The National Institute on Aging (NIA) awarded a $792,074 Project Grant (CFDA 93.866 - Aging Research) to the Trustees of Indiana University (IU Indianapolis) to develop and validate self-delivering small interfering RNA (siRNA) oligonucleotides that efficiently and specifically knockdown INPP5D isoforms in mouse microglia. The long-term goal is to slow or halt the progression of Alzheimer's disease (AD) by modifying microglial function through siRNA-mediated knockdown of INPP5D, a gene...

This $760,207 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a multi-omic integrative analysis of shared and distinct inflammation networks across Alzheimer's disease (AD) and frontotemporal dementia (FTD). The research, led by The Methodist Hospital Research Institute (HMRI) in Houston, TX, aims to: Perform large-scale proteomic analysis of matched serum and cerebrospinal fluid samples from 250 AD patients, 100 FTD patients, and 150...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $314,000.00 to investigate the mechanisms by which the complement system, specifically complement C1Q, contributes to synapse loss in Alzheimer's disease (AD). The project aims to identify the molecular mechanisms driving C1Q-mediated synaptic pruning in response to pathological tau accumulation, a key hallmark of AD. The research will utilize the PS19 mouse model of tauopathy to study...

This $3.38 million project grant from the National Institutes of Health's National Institute on Aging will fund research to repurpose FDA-approved agonists of the HCAR2 receptor as novel therapeutics for Alzheimer's disease. The grantee, Indiana University Iupui, will conduct preclinical studies using the 5XFAD mouse model of Alzheimer's disease to evaluate the therapeutic efficacy and pharmacological targets of the FDA-approved drugs niaspan and dimethyl fumarate in modulating microglial...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $445,625 to Rutgers, The State University to develop an innovative nanotechnology approach to address neuroinflammation in Alzheimer's disease (AD). The project aims to utilize synthetic amphiphilic macromolecule (AM)-based nanoparticles (NPs) that can target scavenger receptors on glial cells, in order to interrupt the formation of fibril amyloid-beta (FAb)-scavenger receptor complexes and...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop and optimize non-invasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The $812,030 award, effective from December 2024 to November 2029, supports research focused on three key objectives: Investigating the relationship between astrocytic acetate metabolism and astrocyte reactivity in an AD model using deuterium-based magnetic resonance...